Wednesday , October 18 2017
Home / Resources / Products / Invokana® (canagliflozin)

Invokana® (canagliflozin)

Invokana® (canagliflozin)

The FDA has approved the first-in-class sodium glucose cotransporter 2 (SGLT2) inhibitor, canagliflozin. Find out all about this new drug — mode of action, contraindications, side effects, weight loss, lower A1c’s, blood pressure and its effect on cholesterol — with this handout for medical professionals. Just follow this link to download the pdf.

Download the Diabetes In Control Invokana (canagliflozin) PDF here.